165 related articles for article (PubMed ID: 32851343)
1. 4SCAR-GD2-modified T-cell therapy in neuroblastoma with
Xu X; Zhao W; Yue Z; Qin M; Jin M; Chang LJ; Ma X
Pediatr Investig; 2020 Mar; 4(1):55-58. PubMed ID: 32851343
[TBL] [Abstract][Full Text] [Related]
2. GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients.
Yu L; Huang L; Lin D; Lai X; Wu L; Liao X; Liu J; Zeng Y; Liang L; Zhang G; Wang B; Wu Z; Tao S; Liu Y; Jiao C; Chang LJ; Yang L
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2643-2652. PubMed ID: 34724115
[TBL] [Abstract][Full Text] [Related]
3. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
[TBL] [Abstract][Full Text] [Related]
4. Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G
Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Kramer K; Modak S; Yataghene K; Cheung NK
Oncoimmunology; 2015 Jul; 4(7):e1016704. PubMed ID: 26140243
[TBL] [Abstract][Full Text] [Related]
5. [Clinical characteristics and prognostic analysis of 458 children with high-risk neuroblastoma in a single center].
Su Y; Ma XL; Wang HM; Qin H; Qin MQ; Zhang FQ; Jin M; Zhang DW; Chen CH; Zeng Q; He LJ; Ni X
Zhonghua Er Ke Za Zhi; 2020 Oct; 58(10):796-801. PubMed ID: 32987457
[No Abstract] [Full Text] [Related]
6. Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma.
Tumino N; Weber G; Besi F; Del Bufalo F; Bertaina V; Paci P; Quatrini L; Antonucci L; Sinibaldi M; Quintarelli C; Maggi E; De Angelis B; Locatelli F; Moretta L; Vacca P; Caruana I
J Hematol Oncol; 2021 Nov; 14(1):191. PubMed ID: 34772439
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model.
Bocca P; Di Carlo E; Caruana I; Emionite L; Cilli M; De Angelis B; Quintarelli C; Pezzolo A; Raffaghello L; Morandi F; Locatelli F; Pistoia V; Prigione I
Oncoimmunology; 2017; 7(1):e1378843. PubMed ID: 29296542
[TBL] [Abstract][Full Text] [Related]
8. Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15.
Chen Y; Sun C; Landoni E; Metelitsa L; Dotti G; Savoldo B
Clin Cancer Res; 2019 May; 25(9):2915-2924. PubMed ID: 30617136
[TBL] [Abstract][Full Text] [Related]
9. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
10.
Kushner BH; LaQuaglia MP; Modak S; Wolden SL; Basu EM; Roberts SS; Kramer K; Yataghene K; Cheung IY; Cheung NV
Oncotarget; 2017 Nov; 8(56):95293-95302. PubMed ID: 29221128
[TBL] [Abstract][Full Text] [Related]
11. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.
Del Bufalo F; De Angelis B; Caruana I; Del Baldo G; De Ioris MA; Serra A; Mastronuzzi A; Cefalo MG; Pagliara D; Amicucci M; Li Pira G; Leone G; Bertaina V; Sinibaldi M; Di Cecca S; Guercio M; Abbaszadeh Z; Iaffaldano L; Gunetti M; Iacovelli S; Bugianesi R; Macchia S; Algeri M; Merli P; Galaverna F; Abbas R; Garganese MC; Villani MF; Colafati GS; Bonetti F; Rabusin M; Perruccio K; Folsi V; Quintarelli C; Locatelli F;
N Engl J Med; 2023 Apr; 388(14):1284-1295. PubMed ID: 37018492
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification.
Huang C; Jiang S; Yang J; Liao X; Li Y; Li S
Medicine (Baltimore); 2020 Jun; 99(25):e20853. PubMed ID: 32569234
[TBL] [Abstract][Full Text] [Related]
13. Significance of hematopoietic surface antigen CD34 in neuroblastoma prognosis and the genetic landscape of CD34-expressing neuroblastoma CSCs.
Aravindan N; Somasundaram DB; Herman TS; Aravindan S
Cell Biol Toxicol; 2021 Jun; 37(3):461-478. PubMed ID: 32979173
[TBL] [Abstract][Full Text] [Related]
14. [Clinical characteristics and prognosis of high-risk neuroblastoma with bone marrow metastasis in children].
Fan HJ; Huang C; Su Y; Wang XD; Zhou YC; Duan C; Zhao W; Zhao Q; Jin M; Ma XL
Zhonghua Er Ke Za Zhi; 2019 Nov; 57(11):863-869. PubMed ID: 31665841
[No Abstract] [Full Text] [Related]
15. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.
Kaneko M; Tsuchida Y; Mugishima H; Ohnuma N; Yamamoto K; Kawa K; Iwafuchi M; Sawada T; Suita S
J Pediatr Hematol Oncol; 2002 Nov; 24(8):613-21. PubMed ID: 12439032
[TBL] [Abstract][Full Text] [Related]
16. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.
Masserot C; Liu Q; Nguyen E; Gattolliat CH; Valteau-Couanet D; Bénard J; Huber C; Ségal-Bendirdjian E
Mol Oncol; 2016 Feb; 10(2):240-52. PubMed ID: 26482175
[TBL] [Abstract][Full Text] [Related]
17. Results of neuroblastoma treatment in Lithuania: a single centre experience.
Juškaitė A; Tamulienė I; Rascon J
Acta Med Litu; 2017; 24(2):128-137. PubMed ID: 28845131
[TBL] [Abstract][Full Text] [Related]
18. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Modak S; Kramer K; Roberts SS; Basu EM; Yataghene K; Cheung NK
Oncotarget; 2016 Jan; 7(4):4155-66. PubMed ID: 26623730
[TBL] [Abstract][Full Text] [Related]
19. Impact of 11q Loss of Heterozygosity Status on the Response of High-Risk Neuroblastoma With MYCN Amplification to Neoadjuvant Chemotherapy.
Lu XY; Qu LJ; Duan XL; Zuo W; Sai K; Rui G; Gong XF; Ding YB; Gao Q
Front Pediatr; 2022; 10():898918. PubMed ID: 35757140
[TBL] [Abstract][Full Text] [Related]
20. Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma.
Liu Z; Zhou J; Yang X; Liu Y; Zou C; Lv W; Chen C; Cheng KK; Chen T; Chang LJ; Wu D; Mao J
Mol Cancer; 2023 Jan; 22(1):3. PubMed ID: 36617554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]